Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00839930 · ClinicalTrials.gov registry record · Phase 1

Cilostazol 50 mg Tablets Under Fasting Conditions

A Phase 1 study of Healthy, sponsored by Teva Pharmaceuticals U.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT00839930: Completed Phase 1 study of Healthy, sponsored by Teva Pharmaceuticals U.

NCT00839930 is a Phase 1 study of Healthy that has completed, run by Teva Pharmaceuticals U. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00839930, a Phase 1 study of Healthy, has completed, sponsored by Teva Pharmaceuticals U.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEVA Pharmaceuticals USA with that of PLETAL Tablets manufactured by Otsuka Pharmaceuticals Co., Ltd. for Otsuka America Pharmaceutical, Inc. following a single oral dose (1 x 50 mg tablet) in healthy adult subjects administered under fasting conditions.

Primary Outcome

Bioequivalence based on Cmax

Conditions Studied

Healthy

Interventions

  • DRUG Cilostazol 50 mg Tablets
  • DRUG Pletal®

Study Locations (2)

Minnesota

  • PRACS Institute Ltd. - East Grand Forks

North Dakota

  • PRACS Institute, Ltd. - Fargo

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2004-02
Est. Completion 2004-02
Phase Phase 1
Teva Pharmaceuticals U

19 total trials

What the finished NCT00839930 record still lists

NCT00839930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Cilostazol 50 mg Tablets is the first listed.

NCT00839930 reports a single indexed study location in Minnesota, North Dakota.

Frequently Asked Questions

What is clinical trial NCT00839930 about?

NCT00839930 is a clinical study titled "Cilostazol 50 mg Tablets Under Fasting Conditions". This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEVA Pharmaceuticals USA with that of PLETAL Tablets manufactured by Otsuka Pharmaceuticals Co., Ltd. for Otsuka Am...

What is the current status of trial NCT00839930?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2004-02. Estimated completion is 2004-02.

What conditions does trial NCT00839930 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00839930?

The interventions under investigation include: Cilostazol 50 mg Tablets (DRUG), Pletal® (DRUG).

Who is sponsoring clinical trial NCT00839930?

This trial is sponsored by Teva Pharmaceuticals U, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00839930 being conducted?

This trial has 2 study locations across Minnesota, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00839930's enrollment target sits among peer trials

30 678th of 1090 higher than 363 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00839930, the US trial registry maintained by the National Library of Medicine. NCT00839930 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.